Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.46
+0.55781.75%
Post-market: 32.460.00000.00%19:30 EDT
Volume:2K
Turnover:49.64K
Market Cap:41.39M
PE:- -
High:32.46
Open:32.27
Low:32.24
Close:31.90
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.40
T/O Rate:0.12%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Shilpa Medicare’s Jadcherla Unit Wins European GMP Nod

TIPRANKS
·
2 hours ago

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
14 hours ago

Moderna Inc. Stock Advances 14.2%, Outperforms Peers

Dow Jones
·
15 hours ago

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Teva announces FDA approval for Weltruza

TIPRANKS
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday

Lilly Says Phase 3b Together-PsO Data Show Broader Biomarker Shifts with Taltz Plus Zepbound vs Taltz Alone

Reuters
·
Yesterday

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday

Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA

TIPRANKS
·
Yesterday

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Yesterday

Citi Lowers Novo Nordisk Price Target to DKK 296: Oral Weight-Loss Pill Sales Outlook Improves, but Margin Growth Remains Weak

Deep News
·
Yesterday

Legend Biotech Corporation : JP Morgan Cuts Target Price to $33 from $35

THOMSON REUTERS
·
Yesterday

Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss Pharma

TIPRANKS
·
Yesterday

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Yesterday

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

MT Newswires Live
·
Oct 08